Arcutis licenses ZORYVE to Sato for Japan; $25M upfront, up to $65M milestones

Arcutis Biotherapeutics, Inc.

Upfront payment of $25M; up to $10M in regulatory milestones and $30M in sales milestones.
Royalties of low double-digit to mid-teen double-digit percentage on net sales in Japan.
Sato exclusively develops and commercializes ZORYVE cream and foam for dermatological indications in Japan.
Arcutis retains approval and oversight rights over development and commercialization activities.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Arcutis Biotherapeutics, Inc. entered into License Agreement with Sato Pharmaceutical Co., Ltd. valued at an upfront payment of $25 million (effective 2024-02-27).

Action: entry
Agreement: license
Counterparty: Sato Pharmaceutical Co., Ltd.
Value: an upfront payment of $25 million
Effective: 2024-02-27

Exact text from the filing

On February 27, 2024, Arcutis Biotherapeutics, Inc. (“Arcutis” or the “Company”) entered into a License Agreement (the “License Agreement”) with Sato Pharmaceutical Co., Ltd. (“Sato”).

View on SEC.gov

746 material agreements filed in the last 30 days. Browse all material agreements →

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-007586

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.